April 12, 2024
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 5, 2024
Praxis Precision Medicines to Participate in Upcoming April Conferences
April 2, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
March 27, 2024
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
March 26, 2024
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 25, 2024
Praxis Precision Medicines to Host PRAX-628 Program Update
March 5, 2024
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 1, 2024
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
February 2, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 14